Skip to main content
. Author manuscript; available in PMC: 2022 Feb 1.
Published in final edited form as: Bone. 2020 Nov 17;143:115762. doi: 10.1016/j.bone.2020.115762

Figure 3: MCP-1 treatment mimics the PTH anabolic effect in trabecular bone of MCP-1 deficient mice.

Figure 3:

All mice were 4-month old males at the start of the injections. (A) Serum MCP-1 levels after different doses of rhMCP-1 injections (0.25, 0.5 and 1 μg/mice) given daily for six days and blood collected 2 h after each of the injections to measure the circulating concentrations of MCP-1 by ELISA. (B) Serum MCP-1 levels after 10 days of daily injections for the conditions shown in the figure (hPTH; hPTH (1–34) at 80 ug/kg to WT mice) and blood collected 2 h after the last injection. (C) Representative μCT images of the trabecular bone of femurs after 6 weeks of the different daily treatment regimes as shown. hPTH (1–34) was given at 80 μg/kg; rhMCP-1 was given at 0.25 μg /mouse. (D–H) μCT analyses of the distal femoral trabecular bone of the treatments in (C) showing BV/TV (%), Tb.Sp (mm), Tb.Th (mm), Tb.N (1/mm) and Tb.Pf (1/mm). Values are expressed as mean ± SEM (n = 8 mice/group). *p < 0.05 and **p < 0.01 compared to saline-injected WT mice.